Nonetheless, these findings highlight the potential of NXT-2 as a single, pan-fungal vaccine candidate and support the rationale for advancing both vaccine- and antibody-based therapeutic strategies to protect vulnerable populations from life-threatening fungal infections. The gene discussed is NXT2; the disease is fungal infectious disease.